Analyst desks were busy Monday, with target price tweaks hitting pharma, fast food, and cybersecurity names.
Gilead Sciences took the most notable hit. The biotech's consensus target fell to $157.96 from $158.07. That may look minor, but the directional shift is bearish — 22 of 30 covering analysts now rate it a sell. Gilead carries a $163B market cap. Short interest sits at just 1.8% of free float, suggesting bears are betting through ratings rather than shorts.
Palo Alto Networks got a lift. The average target nudged up to $207.56 from $206.46. With 44 analysts covering it and a $168B market cap, the cybersecurity giant remains a Wall Street favourite. Short interest is a low 3.1% of free float.
McDonald's saw its consensus target tick down to $333.36 from $333.97. The quick-service giant faces pressure from a weakening consumer backdrop. Twenty of 36 covering analysts hold a sell or underweight view.
In residential real estate, a wave of target changes swept apartment REITs. Essex Property Trust, Camden Property Trust, and all received modest upward revisions, signalling cautious optimism on Sun Belt housing demand.
SLB also saw its target nudged higher to $61.39, with 24 of 28 analysts still bullish on the oilfield services firm.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
